Altering cancer transcriptomes using epigenomic inhibitors
收藏官方服务：
资源简介：
Altering cancer transcriptomes using epigenomic inhibitors
应用场景：
创建时间：
2015-01-07
相关数据集
Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
An "induced PARP inhibitor (PARPi) sensitivity by epigenetic modulation" strategy is being evaluated in the clinic to sensitize homologous recombination (HR) proficient tumors to PARPi treatments. To
NIAID Data Ecosystem70
SMARCA4 Phosphorilation inhibition
Cyclin-Dependent Kinase 9 (CDK9) as part of the PTEFb complex promotes transcriptional elongation and high-level gene expression. We now report that, paradoxically, CDK9 is also essential for maintain
NIAID Data Ecosystem30
Additional file 4 of Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas
Additional file 4. Table S3. Induced expression of apoptosis-related genes.
Figshare2024-09-11 更新20
Mus musculus Transcriptome or Gene expression
Transcriptome sequencing results of epididymal adipose tissue from mice on a high-fat diet supplemented with nuciferine and mice on a high-fat diet without nuciferine. To investigate the effect of nuc
NIAID Data Ecosystem40
Glucocorticoid- and Pioglitazone-Induced Proteinuria Reduction in Experimental Nephrotic Syndrome Both Correlate with Glomerular ECM Modulation. Glucocorticoid- and Pioglitazone-Induced Proteinuria Reduction in Experimental Nephrotic Syndrome Both Correlate with Glomerular ECM Modulation
Idiopathic nephrotic Syndrome (NS) is a common glomerular disease. While glucocorticoids (GC) are the primary treatment, the PPARγ agonist pioglitazone (Pio) also reduces proteinuria in patients with
NIAID Data Ecosystem30
